BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34521767)

  • 1. Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.
    Andrijes R; Hejmadi RK; Pugh M; Rajesh S; Novitskaya V; Ibrahim M; Overduin M; Tselepis C; Middleton GW; Győrffy B; Beggs AD; Berditchevski F
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34521767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
    JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
    Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
    J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
    Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
    World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
    Weinberg BA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSPAN6 is a suppressor of Ras-driven cancer.
    Humbert PO; Pryjda TZ; Pranjic B; Farrell A; Fujikura K; de Matos Simoes R; Karim R; Kozieradzki I; Cronin SJF; Neely GG; Meyer TF; Hagelkruys A; Richardson HE; Penninger JM
    Oncogene; 2022 Apr; 41(14):2095-2105. PubMed ID: 35184157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
    Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
    Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
    [No Abstract]   [Full Text] [Related]  

  • 12. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
    Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
    Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
    Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
    Yang G; Huang L; Jia H; Aikemu B; Zhang S; Shao Y; Hong H; Yesseyeva G; Wang C; Li S; Sun J; Zheng M; Ma J
    Oncogene; 2021 Oct; 40(41):5993-6006. PubMed ID: 34385595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.